Record-Breaking Price Performance
On 28 Jul 2026, Sun Pharmaceutical Industries Ltd’s stock surged to Rs.1988, marking its highest-ever closing price. This new peak represents a 0.96% gain on the day, outperforming the Sensex which marginally declined by 0.01%. The stock has demonstrated consistent upward momentum, having gained 2.37% over the past two consecutive trading days and outperforming its sector by 0.61% today.
The stock’s trading range remained relatively narrow at Rs.16.95, indicating a stable price movement near this historic high. Notably, the share price is trading above all key moving averages — 5-day, 20-day, 50-day, 100-day, and 200-day — underscoring a strong bullish technical trend.
Long-Term Outperformance Against Benchmarks
Sun Pharma’s price appreciation over various time horizons has been impressive when compared to the broader market. Over the past year, the stock has delivered a 17.55% return, significantly outpacing the Sensex’s decline of 5.02%. Year-to-date, the stock has risen 15.86%, while the Sensex has fallen 9.85%. Over three years, the company’s shares have appreciated by 75.13%, compared to the Sensex’s 16.13% gain. Even over five years, the stock has surged 189.80%, far exceeding the Sensex’s 46.50% increase.
These figures highlight Sun Pharma’s consistent ability to generate shareholder value and outperform the broader market indices over multiple time frames.
Strong Fundamental Backing
Sun Pharmaceutical Industries Ltd is classified as a large-cap company with a market capitalisation of Rs.4,74,277 crores, making it the largest entity in the Pharmaceuticals & Biotechnology sector. It accounts for 17.33% of the sector’s market capitalisation and contributes 12.03% of the industry’s annual sales, which stand at Rs.58,462.04 crores.
The company’s financial health is underpinned by its net-debt-free status and strong long-term growth metrics. Over the past five years, net sales have grown at an annualised rate of 11.78%, while operating profit has expanded at 18.20% per annum. The average return on equity (ROE) of 15.58% reflects efficient utilisation of shareholders’ funds and sustained profitability.
Institutional investors hold a significant 36.71% stake in the company, indicating strong confidence from well-resourced market participants who typically conduct rigorous fundamental analysis.
Quality and Valuation Metrics
Sun Pharma is recognised as an excellent quality company by MarketsMOJO, with a current Mojo Score of 72.0 and a Mojo Grade upgraded from Hold to Buy on 8 Jun 2026. The company ranks among the top 1% of over 4,000 stocks analysed by MarketsMOJO, reflecting its superior financial and operational quality.
Key quality indicators include a very low debt-to-EBITDA ratio of 0.26, an average EBIT to interest coverage ratio of 52.05x, and a net cash position with a negative net debt-to-equity ratio of -0.33. The company also maintains a strong return on capital employed (ROCE) averaging 22.23%, further highlighting its efficient capital management.
Dividend metrics show a yield of 0.81% with a payout ratio of 35.13%, and the latest dividend declared was Rs.5 per share, with an ex-dividend date of 7 Jul 2026.
Valuation Considerations
Despite the strong fundamentals and market leadership, Sun Pharma’s valuation metrics indicate a premium pricing relative to peers. The stock trades at a price-to-earnings (P/E) ratio of 38x (TTM) and a price-to-book value (P/BV) of 5.68x. The enterprise value to EBITDA ratio stands at 25.17x, while the PEG ratio is 4.21x, signalling a relatively expensive valuation compared to historical averages and sector peers.
This premium reflects the market’s recognition of the company’s quality and growth prospects, although it also suggests that investors are paying a higher multiple for the stock’s earnings and growth potential.
Recent Financial Trends
While the stock has reached new highs, recent quarterly financials show some moderation. Profit before tax (PBT) less other income for the quarter ended March 2026 was Rs.3,092.84 crores, down 13.9% compared to the previous four-quarter average. Similarly, profit after tax (PAT) for the same period was Rs.2,714.03 crores, a decline of 10.6% versus the prior four-quarter average.
These figures indicate a flat short-term financial trend, though they have not impeded the stock’s upward price trajectory.
Technical Analysis and Market Sentiment
The overall technical trend for Sun Pharma is bullish, with the trend having shifted to this stance on 10 Jun 2026 at a price of Rs.1787.10. Weekly and monthly technical indicators such as MACD and Bollinger Bands are also bullish, supporting the positive momentum.
Key support levels include the 52-week low of Rs.1547.25, while immediate resistance was recently overcome at Rs.1925.63 (20-day moving average). The stock’s ability to sustain above these technical levels reinforces the strength of the current uptrend.
Delivery volumes have surged, with a 1-day delivery change of 280.57% compared to the 5-day average, and a 1-month delivery volume increase of 12.65%, indicating strong participation from long-term holders and institutional investors.
Conclusion
Sun Pharmaceutical Industries Ltd’s ascent to an all-time high of Rs.1988 on 28 Jul 2026 marks a significant achievement for the company and its shareholders. Supported by robust fundamentals, consistent long-term growth, and strong technical momentum, the stock has outperformed both its sector and the broader market indices over multiple time frames.
While recent quarterly earnings have shown some softness, the company’s excellent quality metrics, net-debt-free status, and market leadership position underpin its current valuation and price performance. The premium valuation multiples reflect the market’s confidence in Sun Pharma’s enduring strength within the Pharmaceuticals & Biotechnology sector.
